Recent research conducted by scientists at University College London has cast new light on the escalating risks associated with the rising global use of gabapentinoids, a class of medications frequently prescribed for chronic pain, epilepsy, and anxiety disorders. These drugs, principally gabapentin and pregabalin, have gained popularity largely because they are perceived as safer alternatives to opioids, which are notorious for their high addiction potential and significant side-effect profiles. However, findings published in PLOS Medicine reveal that gabapentinoids, when combined with certain other medications such as benzodiazepines or opioids, dramatically increase the likelihood of drug poisoning requiring hospitalization.
The study, which utilized a self-controlled case series methodology, analyzed data spanning a decade from UK patients prescribed gabapentinoids between 2010 and 2020. This approach enabled researchers to compare periods when individuals were using gabapentinoids with times they were not, providing robust evidence that initiation of gabapentinoid therapy corresponds with a marked surge in drug poisoning risk. Particularly alarming was the revelation that combining gabapentinoids with benzodiazepines doubled the risk of hospital admission due to poisoning, while concurrent use with opioids resulted in a 30% increase in such events.
Intriguingly, the research identified that the highest susceptibility to drug poisoning was not after beginning gabapentinoids, but rather in the three months preceding their initiation. This suggests a period of clinical vulnerability during which patients may be exposed to heightened risks, possibly due to the worsening of symptoms that prompt the prescriptive decision. While there is a slight reduction in risk following the start of gabapentinoid treatment, patients remain at significantly elevated risk for several months, indicating that gabapentinoids may not provide the expected protective effect against medication-related harm.
Gabapentinoids exert their therapeutic effect by modulating calcium channels in the nervous system, thereby dampening excitatory neurotransmitter release, which is beneficial for neuropathic pain and seizure control. Despite their mechanistic advantages and widespread acceptance, their sedative properties appear to enhance the central nervous system depressant effects of other co-administered drugs. This pharmacodynamic interaction likely explains the augmented risk of drug poisoning observed when gabapentinoids are combined with opioids or benzodiazepines, both of which also depress respiratory function.
The evidence presented highlights a critical clinical challenge: the high rates of polypharmacy in patients prescribed gabapentinoids. A striking 89% of participants had been treated concurrently with opioids, and 55% with benzodiazepines at some point during the study period. The coexistence of these medications on such a large scale underscores the complexity of managing patients with chronic pain or psychiatric conditions and stresses the importance of careful medication reconciliation and monitoring.
Furthermore, the study’s inclusive criteria encompassed both intentional and accidental drug poisonings, including cases of overdose and misuse, reflecting the real-world complexities inherent in pharmaceutical management. Symptoms leading to hospitalization varied and could involve loss of consciousness, respiratory depression, or seizures, all of which signify potentially life-threatening conditions. Given this spectrum of clinical presentation, timely identification of at-risk patients and early intervention could be critical in reducing morbidity.
This research is particularly relevant in the context of the ongoing opioid epidemic and the search for safer analgesic alternatives. Gabapentinoids have frequently been positioned as a viable substitute to opioids; however, this study’s findings caution against complacency. Clinicians should remain vigilant when prescribing these medications, especially in combinations known to potentiate sedative effects. Such vigilance includes assessing patient history for substance abuse, potential drug interactions, and close follow-up after initiation.
The findings align with recent updates from the UK’s Medicines and Healthcare products Regulatory Agency, which has reinforced warnings about the addictive potential, tolerance development, withdrawal phenomena, and misuse of gabapentinoids. Although the precise mechanisms by which gabapentinoids contribute to drug poisoning remain incompletely defined, their ability to amplify sedative effects is a plausible explanation supported by emerging pharmacological data.
This study was made possible through extensive collaboration among UCL’s School of Pharmacy, Division of Psychiatry, University College London Hospitals, the University of Hong Kong, and Aston University. Funding was provided by the NIHR UCLH Biomedical Research Centre, reflecting a commitment to advancing understanding of drug safety in clinical practice.
In conclusion, while gabapentinoids remain valuable tools in the pharmacologic armamentarium for epilepsy, neuropathic pain, and anxiety disorders, this study underscores the considerable risks embedded in their use, particularly when prescribed alongside benzodiazepines or opioids. These findings advocate for enhanced prescriber awareness, stricter monitoring protocols, and potentially the development of guidelines aimed at mitigating adverse outcomes associated with these increasingly common drug regimens. As the medical community grapples with balancing efficacy and safety, this research offers critical insights into optimizing patient care to prevent drug-related harm.
Subject of Research: People
Article Title: Association between gabapentinoid treatment, concurrent use with opioid or benzodiazepine and the risk of drug poisoning: A self-controlled case series study
News Publication Date: 16-Apr-2026
References:
- PLOS Medicine, DOI: 10.1371/journal.pmed.1005035
Keywords:
Gabapentinoids, gabapentin, pregabalin, drug poisoning, drug safety, drug interactions, opioids, benzodiazepines, chronic pain, epilepsy, pharmacology, medication risks
